Join Dr. Justin Moser and Dr. Meredith McKean to learn more about the approval of KIMMTRAK and what this means for you as a patient, whether you are HLA-0201 positive and qualify for this treatment drug, or if you do not and wonder what is out there treatment wise for you.


Dr. Moser is a Medical Oncologist who specializes in phase 1 clinical trials, drug development, and cutaneous malignancies. He leads the Melanoma program at HonorHealth Research Institute, and runs one of the only programs dedicated to uveal melanoma in Arizona.
 
Dr. Meredith McKean received her bachelor's degree from Iowa State University, where the promising athlete ran cross-country and track. McKean completed her fellowship in Hematology-Oncology at the University of Texas MD Anderson Cancer Center.   She now serves as the associate director for the Melanoma and Skin Cancer Research Program at the Sarah Cannon Research Institute of Tennessee Oncology.